232 related articles for article (PubMed ID: 24920230)
1. Fusogenic pH sensitive liposomal formulation for rapamycin: improvement of antiproliferative effect.
Ghanbarzadeh S; Khorrami A; Mohamed Khosroshahi L; Arami S
Pharm Biol; 2014 Jul; 52(7):848-54. PubMed ID: 24920230
[TBL] [Abstract][Full Text] [Related]
2. Fusogenic liposomal formulation of sirolimus: improvement of drug anti-proliferative effect on human T-cells.
Valizadeh H; Ghanbarzadeh S; Zakeri-Milani P
Drug Dev Ind Pharm; 2015; 41(9):1558-65. PubMed ID: 25311425
[TBL] [Abstract][Full Text] [Related]
3. Improvement of the antiproliferative effect of rapamycin on tumor cell lines by poly (monomethylitaconate)-based pH-sensitive, plasma stable liposomes.
Ghanbarzadeh S; Arami S; Pourmoazzen Z; Khorrami A
Colloids Surf B Biointerfaces; 2014 Mar; 115():323-30. PubMed ID: 24394948
[TBL] [Abstract][Full Text] [Related]
4. Plasma stable, pH-sensitive non-ionic surfactant vesicles simultaneously enhance antiproliferative effect and selectivity of Sirolimus.
Ghanbarzadeh S; Khorrami A; Pourmoazzen Z; Arami S
Pharm Dev Technol; 2015 May; 20(3):279-87. PubMed ID: 24266760
[TBL] [Abstract][Full Text] [Related]
5. Plasma stable, pH-sensitive fusogenic polymer-modified liposomes: A promising carrier for mitoxantrone.
Ghanbarzadeh S; Arami S; Pourmoazzen Z; Ghasemian-Yadegari J; Khorrami A
J Biomater Appl; 2014 Jul; 29(1):81-92. PubMed ID: 24336315
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells.
Rouf MA; Vural I; Renoir JM; Hincal AA
J Liposome Res; 2009; 19(4):322-31. PubMed ID: 19863167
[TBL] [Abstract][Full Text] [Related]
7. The enhancement of immunosuppressive effects of cyclosporine A on human T-cells using fusogenic liposomes.
Malaekeh-Nikouei B; Jaafari MR; Tabassi SA; Samiei A
Colloids Surf B Biointerfaces; 2008 Dec; 67(2):238-44. PubMed ID: 18930640
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
9. Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression.
Maitani Y; Igarashi S; Sato M; Hattori Y
Int J Pharm; 2007 Sep; 342(1-2):33-9. PubMed ID: 17566677
[TBL] [Abstract][Full Text] [Related]
10. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
[TBL] [Abstract][Full Text] [Related]
11. Fusogenic activity of PEGylated pH-sensitive liposomes.
Vanić Z; Barnert S; Süss R; Schubert R
J Liposome Res; 2012 Jun; 22(2):148-57. PubMed ID: 22149717
[TBL] [Abstract][Full Text] [Related]
12. Preparation and properties evaluation of a novel pH-sensitive liposomes based on imidazole-modified cholesterol derivatives.
Ju L; Cailin F; Wenlan W; Pinghua Y; Jiayu G; Junbo L
Int J Pharm; 2017 Feb; 518(1-2):213-219. PubMed ID: 27889588
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
14. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system.
Tagami T; Ernsting MJ; Li SD
J Control Release; 2011 Sep; 154(3):290-7. PubMed ID: 21640149
[TBL] [Abstract][Full Text] [Related]
15. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
[TBL] [Abstract][Full Text] [Related]
16. Ethanol-based proliposome delivery systems of paclitaxel for in vitro application against brain cancer cells.
Najlah M; Jain M; Wan KW; Ahmed W; Albed Alhnan M; Phoenix DA; Taylor KMG; Elhissi A
J Liposome Res; 2018 Mar; 28(1):74-85. PubMed ID: 27834116
[TBL] [Abstract][Full Text] [Related]
17. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus encapsulated liposomes for cancer therapy: physicochemical and mechanical characterization of sirolimus distribution within liposome bilayers.
Onyesom I; Lamprou DA; Sygellou L; Owusu-Ware SK; Antonijevic M; Chowdhry BZ; Douroumis D
Mol Pharm; 2013 Nov; 10(11):4281-93. PubMed ID: 24099044
[TBL] [Abstract][Full Text] [Related]
19. Expression of luciferase plasmid (pCMVLuc) entrapped in DPPC/cholesterol/DDAB liposomes in HeLa cell lines.
Manosroi A; Thathang K; Manosroi J; Werner RG; Schubert R; Peschka-Süss R
J Liposome Res; 2009; 19(2):131-40. PubMed ID: 19515000
[TBL] [Abstract][Full Text] [Related]
20. Membrane interactions of ternary phospholipid/cholesterol bilayers and encapsulation efficiencies of a RIP II protein.
Manojlovic V; Winkler K; Bunjes V; Neub A; Schubert R; Bugarski B; Leneweit G
Colloids Surf B Biointerfaces; 2008 Jul; 64(2):284-96. PubMed ID: 18359207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
